Assessment of baseline symptom burden in treatment-naïve patients with lung cancer: an observational study

Mendoza, Tito R.; Kehl, Kenneth L.; Bamidele, Oluwatosin; Williams, Loretta A.; Shi, Qiuling; Cleeland, Charles S.; Simon, George R.

doi:10.1007/s00520-018-4632-0

Cited by 44 publications

(38 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The prevalence of symptoms at baseline differed according to the site of the primary tumor, as also reported elsewhere [24,25]. The association between specific tumor sites and cancer symptoms is clear, even at advanced stages of the disease when widespread metastasis can dilute this specificity.…”

Section: Discussionsupporting

confidence: 68%

Impact of Palliative Care in Evaluating and Relieving Symptoms in Patients with Advanced Cancer. Results from the DEMETRA Study

Corli

Pellegrini²,

Bosetti

et al. 2020

IJERPH

View full text Add to dashboard Cite

Background: Cancer patients experience multiple symptoms throughout the course of the disease. We aimed to provide a comprehensive analysis of the symptom burden in patients with advanced cancer at admission to specialist palliative care (PC) services and seven days later to estimate the immediate impact of PC intervention. Patient and methods: The analysis was based on an observational, prospective, multicenter study (named DEMETRA) conducted in Italy on new patients accessing network specialist PC centers during the period May 2017–November 2017. The prevalence and intensity of symptoms were assessed at baseline and after seven days using three tools including the Edmonton Symptom Assessment System (ESAS). Results: Five PC centers recruited 865 cancer patients. Thirty-three different symptoms were observed at the baseline, the most frequent being asthenia (84.9%) and poor well-being (71%). The intensity of the most frequent symptoms according to ESAS ranged from 5.5 for asthenia to 3.9 for nausea. The presence and intensity of physical symptoms increased with increasing levels of anxiety and depression. After seven days, prevalence of nausea and breathlessness as well as intensity of almost all symptoms significantly decreased. Conclusions: The study confirmed the considerable symptom burden of patients with advanced cancer. PC intervention has significantly reduced the severity of symptoms, despite the patients’ advanced disease and short survival.

show abstract

Section: Discussionsupporting

confidence: 68%

Impact of Palliative Care in Evaluating and Relieving Symptoms in Patients with Advanced Cancer. Results from the DEMETRA Study

Corli

Pellegrini²,

Bosetti

et al. 2020

IJERPH

View full text Add to dashboard Cite

show abstract

“…The prevalence of symptoms at baseline differed according to the site of the primary tumor, as also reported elsewhere [22,23]. The association between speci c tumor sites and cancer symptoms is clear, even at advanced stages of the disease when widespread metastasis can dilute this speci city.…”

Section: Discussionsupporting

confidence: 66%

Impact of Palliative Care in Evaluating and Relieving Symptoms in Patients with Advanced Cancer. The DEMETRA Study

Corli

Pellegrini²,

Bosetti

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Cancer patients experience a number of symptoms throughout the course of the disease. We aimed to provide a comprehensive analysis of the symptom burden in patients with advanced cancer at admission to specialist palliative care (PC) services and seven days later, to estimate the immediate impact of PC intervention.Patient and methods: The analysis was based on an observational, prospective, multicenter study (named DEMETRA) conducted in Italy to outline the profile of patients, families and PC services in different care settings (hospital, hospice and home care). The prevalence and intensity of symptoms were assessed using three tools, including the Edmonton Symptom Assessment System (ESAS).Results: Five PC centers recruited 865 cancer patients. Thirty-three different symptoms were observed at baseline, the most frequent being asthenia (85%) and lack of appetite (71%). Two-thirds of patients experienced six to twelve simultaneous symptoms. The intensity of the most frequent symptoms according to ESAS varied from 5.5 for asthenia to 3.9 for nausea. The presence and intensity of physical symptoms increased with increasing levels of anxiety and depression. After seven days, prevalence decreased significantly only for nausea and breathlessness, while intensity diminished significantly for almost all symptoms. At admission we noted a correlation between patients' symptoms and the care setting. After one week, the symptom intensity was uniformly reduced in all settings.Conclusions: The study confirmed the considerable symptom burden of patients with advanced cancer. PC intervention significantly lessened the severity of symptoms, despite the patients’ advanced disease and short survival.

show abstract

“…This scale does not evaluate coughing, a common symptom in lung cancer; as a standard of care and in clinical trials, the MDASI-LC test, which includes coughing, must be used to a complete evaluation of the patient's symptoms. 60 Widely used PRObased symptom assessment tools are needed to facilitate a comparison of results with those of other published studies. 61 Only one study 62 reported the use of a new electronic PRO: the NSCLC-SAQ, after Food and Drug Administration (FDA) qualification, will be publicly available to capture patient-reported NSCLC-related symptoms via electronic data entry platforms.…”

Section: Resultsmentioning

confidence: 99%

“…It must be emphasized that there is much evidence in the literature about the benefits of collecting and using PROs in lung cancer populations, for treatment monitoring, 35,[38][39][40][44][45][46][47][48]51,55,[57][58][59][65][66][67] detection of symptoms, 36,37,41,50,53,54,60,65 the role of patient or pathology characteristics on QoL, 40,42,56,68 to improve patientclinician communication and patient satisfaction. 43,61,62 Only one study about the effect of disease progression on QoL was identified 49 assessing the use of PROs related to efficacy outcomes (PFS, OS).…”

Section: Discussionmentioning

confidence: 99%

<p>Feasibility and Utility of Incorporating Patient-Reported Outcomes into Surveillance Strategies for Advanced Lung Cancer</p>

Cavanna¹,

Citterio²,

Orlandi³

2020

PROM

View full text Add to dashboard Cite

To identify and to describe patient-reported outcomes (PROs) in lung cancer patients and to evaluate the feasibility and utility of PROs into surveillance strategies, a review was carried out. Patients and Methods: A systematic search in bibliographic databases evaluating the instruments used in PROs of non-small-Cell lung cancer (NSCLC) patients was done. Results: From August 2014 to August 2019, 33 studies were included in this review and 16,491 patients were evaluated. PROs were divided into 6 different categories: 1) PROs as a guide in therapeutic choice, 2) PROs as indicator of disease progression, 3) agreement between PROs and the evaluated parameters, 4) PROs to evaluate the effects of immunotherapy, 5) need to deepen the knowledge of PROs, and 6) use of new electronic PROs. Conclusion: The most frequently used instruments are EORTC QLQ-30 (16, 50%) and EORTC LC-13 (14, 43.75%) and in some studies (37.5%) they are used together. For different reasons (disease progression, adverse event, death, incomplete participation, etc.), the completion of these instruments decreased over time from baseline to subsequent measurements. This review demonstrates that PROs can play an important role as part of health care, and that routine use implementation could improve patient management in addition to the traditionally collected outcome.

show abstract

Assessment of baseline symptom burden in treatment-naïve patients with lung cancer: an observational study

Cited by 44 publications

References 23 publications

Impact of Palliative Care in Evaluating and Relieving Symptoms in Patients with Advanced Cancer. Results from the DEMETRA Study

Impact of Palliative Care in Evaluating and Relieving Symptoms in Patients with Advanced Cancer. Results from the DEMETRA Study

Impact of Palliative Care in Evaluating and Relieving Symptoms in Patients with Advanced Cancer. The DEMETRA Study

<p>Feasibility and Utility of Incorporating Patient-Reported Outcomes into Surveillance Strategies for Advanced Lung Cancer</p>

Contact Info

Product

Resources

About